Meta Information
ID:cjc-1295
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-20
Model
agent_curation_2026_05_20_peptides
Interactions
Target id:
/condition/fda-compounding-risk
Target name:
FDA-Identified Compounding Safety Risk
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
CJC-1295 is not FDA-approved and is not on any FDA-approved bulk compounding list. The FDA compounding advisory page and the 2023 Therapeutic Peptides review confirm CJC-1295's status as 'not yet FDA-approved,' meaning it lacks the regulatory designation that would permit compounding under 503A or 503B. Compounded CJC-1295 products are unapproved drugs with no quality standards verification.
Actionable advice:
CJC-1295 has no FDA-approved formulation and is not on the 503A or 503B bulk compounding lists. Any compounded CJC-1295 is an unapproved drug. Use entails unknown quality, purity, and safety risks.
Validation status:
validated_via_regulatory
Evidence tier:
tier_b
Evidence basis:
regulatory_advisory_verbatim
Evidence anchors:
Exact phrase from label:
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
Label source:
US FDA compounding advisory. CJC-1295 is an unapproved GHRH analog - NOT FDA-approved and NOT on any FDA-approved bulk compounding list. It was NOT among the 12 peptides FDA removed from Category 2 on 2026-04-15.
Action type:
informational_none
Target id:
/condition/active-cancer
Target name:
Active Cancer / Malignancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
CJC-1295 causes sustained elevation of GH and IGF-1. IGF-1 is a potent cellular growth promoter with mitogenic effects across many cell types. Epidemiological data associate elevated IGF-1 with increased risk of certain cancers. In individuals with active malignancy, CJC-1295 is strongly contraindicated due to potential for IGF-1-driven tumor growth promotion.
Actionable advice:
Active malignancy is a strong contraindication. Do not use in individuals with active or recent cancer history.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
We observed positive associations between circulating IGF-1 and overall cancer risk for both men (HR = 1.03 per 5-nmol/L increment in IGF-1; 95% CI, 1.01-1.06) and women (HR = 1.03; 95% CI, 1.01-1.06).
Label source:
UK Biobank cohort, PMID 32856611. Two-step: CJC-1295 sustainedly raises IGF-1 (PMID 16352683), and elevated IGF-1 is linked to higher overall cancer risk here. Associations are modest and site-divergent.
Action type:
avoid
Target id:
/condition/diabetic-retinopathy
Target name:
Diabetic Retinopathy or Proliferative Retinopathy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Proliferative retinopathies are relative contraindications for CJC-1295 due to the potential for IGF-1-mediated worsening. IGF-1 promotes angiogenesis and may exacerbate neovascularization in the retina.
Actionable advice:
CJC-1295 should be avoided in patients with diabetic retinopathy or other proliferative retinopathies. An eye examination is recommended before any use in diabetic patients.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Mechanistic inference: CJC-1295 raises GH/IGF-1, and the GH/IGF-1 axis is a recognized pro-angiogenic driver of retinal neovascularization, so it could worsen proliferative retinopathy. FLAG: the cited PMID 15056499 is about somatostatin analogues INHIBITING angiogenesis, not IGF-1 worsening retinopathy - mechanism sound, citation only analogical.
Label source:
Class inference
Action type:
avoid
Target id:
/class/ghrps-ghrhs
Target name:
Growth Hormone Releasing Peptides (e.g., Ipamorelin, GHRP-6)
Severity:
major
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
CJC-1295 (a GHRH analog) and GHRPs such as ipamorelin act on different receptors in the pituitary — GHRH receptor vs. ghrelin receptor (GHS-R1a) — leading to a powerful synergistic release of GH far greater than either compound alone. This combination is commonly used but amplifies all GH-related effects and risks proportionally.
Actionable advice:
Combining CJC-1295 with a GHRP (e.g., ipamorelin) amplifies growth-hormone side effects (fluid retention, insulin resistance, carpal tunnel). Use the lowest effective doses and monitor fasting glucose and IGF-1.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Established pharmacology: GHRH analogs (CJC-1295) act on the pituitary GHRH receptor while GHRPs (ipamorelin) act on the ghrelin/GHS-R1a receptor, so co-use produces synergistic GH release exceeding either alone. FLAG: cited PMID 42021992 mentions both agents but does not state the distinct-receptor synergy verbatim - class-level mechanism.
Label source:
Class inference
Action type:
adjust_with_prescriber
Target id:
/dietary/high-carbohydrate-meal
Target name:
High Carbohydrate or High Fat Meal
Severity:
major
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
1
Description:
Elevated blood glucose and insulin from carbohydrate- or fat-rich meals strongly inhibit pituitary GH release via somatostatinergic feedback, blunting the effect of CJC-1295. This pharmacodynamic interaction reduces the GH secretagogue response.
Actionable advice:
Administer at least 2 hours after your last meal and wait at least 1 hour before eating to maximize GH response.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Established endocrine physiology: postprandial hyperglycemia/hyperinsulinemia stimulate hypothalamic somatostatin, which suppresses GH secretion and blunts a GHRH analog's effect. FLAG: cited PMID 16352683 is the CJC-1295 PK trial and does not address meals/somatostatin - mechanism is textbook.
Label source:
Class inference
Action type:
separate
Target id:
/class/corticosteroids
Target name:
Glucocorticoids (Systemic Corticosteroids)
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Glucocorticoids suppress GH secretion and reduce pituitary responsiveness to GHRH. Co-administration with systemic glucocorticoids blunts the GH response to CJC-1295 through enhanced somatostatin tone and direct pituitary suppression.
Actionable advice:
Systemic glucocorticoid use significantly reduces the GH-stimulating effect of CJC-1295. Monitor IGF-1 levels to confirm adequate response if co-administered.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Glucocorticoids exert multiple growth-suppressing effects, interfering with endocrine (e.g., endogenous GH secretion) and metabolic (e.g., bone formation, nitrogen retention, collagen formation) processes essential for normal growth.
Label source:
Peptide Biologix Research Monograph: Cjc 1295
Action type:
monitor
Target id:
/class/somatostatin-analogs
Target name:
Somatostatin Analogs (e.g., Octreotide, Lanreotide)
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Somatostatin analogs directly suppress GH secretion and antagonize the pharmacological effects of CJC-1295. Co-administration eliminates the GH-stimulating effect of CJC-1295.
Actionable advice:
CJC-1295 should not be co-administered with somatostatin analogs; direct pharmacological antagonism renders CJC-1295 ineffective.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The inhibition of growth hormone (GH) secretion by the hypothalamic peptide, somatostatin, is mediated by two critical factors: the concentration of the peptide in hypothalamic portal plasma and the number of somatostatin (SRIF) receptors on the somatotroph.
Label source:
Peptide Biologix Research Monograph: Cjc 1295
Action type:
informational_none
Target id:
/biomarker/igf-1
Target name:
IGF-1 Level Monitoring
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
CJC-1295 elevates IGF-1 in a sustained, dose-dependent manner. Supraphysiological IGF-1 levels are associated with insulin resistance, soft tissue overgrowth, and potentially increased cancer risk. Monitoring IGF-1 is essential to ensure therapeutic levels rather than excess.
Actionable advice:
IGF-1 is best monitored at baseline and periodically during use, targeting the age-appropriate mid-to-upper normal range. The dose is best discontinued or reduced if IGF-1 rises above upper normal limits.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d.
Label source:
Teichman et al. (CJC-1295 PK trial), PMID 16352683. Directly supports sustained IGF-1 elevation; monitor.
Action type:
avoid
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Pregnancy is a contraindication for CJC-1295 in the absence of safety data. GH/IGF-1 axis modulation during pregnancy carries unknown fetal risks.
Actionable advice:
CJC-1295 should not be used during pregnancy or lactation.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/class/antidiabetic-medications
Target name:
Antidiabetic Medications (Insulin, Metformin, SGLT2i)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
GH elevation from CJC-1295 can cause transient insulin resistance by increasing lipolysis and hepatic glucose output. This may reduce the effectiveness of antidiabetic medications and require dose adjustments in diabetic patients. Uncontrolled diabetes mellitus warrants caution.
Actionable advice:
Fasting glucose and HbA1c should be monitored when using CJC-1295 in patients with diabetes or insulin resistance. Antidiabetic medication doses may require adjustment.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
increases in blood glucose because of decreases in insulin sensitivity
Label source:
Sigalos & Pastuszak 2018 (GH-secretagogue safety review), PMID 28400207. GH elevation reduces insulin sensitivity, which can blunt antidiabetic efficacy and require dose adjustment.
Action type:
adjust_with_prescriber
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is not known if CJC-1295 is excreted in human milk or what its effects would be on a nursing infant.
Actionable advice:
It should be avoided completely while breastfeeding.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/pituitary-disorder
Target name:
Pituitary Gland Disorders
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Stimulating a dysfunctional or tumor-affected pituitary gland can have unpredictable and potentially harmful effects on hormone regulation.
Actionable advice:
Use is contraindicated unless under the direct supervision of an endocrinologist.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
Depending on its size and location, the adenoma may press against other tissue and affect other hormones your pituitary gland makes.
Label source:
Anecdotal: Cleveland Clinic
Action type:
avoid
Target id:
/circadian/sleep
Target name:
Going to Sleep
Severity:
moderate
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0.5
Hours after target:
0
Description:
The largest natural pulse of growth hormone occurs during the first few hours of deep sleep; administering CJC-1295 before bed amplifies this natural rhythm.
Actionable advice:
Administer within 30 minutes of going to bed on an empty stomach.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
separate
Target id:
/condition/diabetes-mellitus
Target name:
Diabetes Mellitus
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Growth hormone has a counter-regulatory effect to insulin, meaning it can raise blood glucose levels and increase insulin resistance, potentially disrupting glycemic control.
Actionable advice:
This is best used with extreme caution under medical supervision, with frequent blood glucose monitoring.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
monitor
Target id:
/class/hyperglycemic-agents
Target name:
Drugs that Raise Blood Sugar (e.g., Corticosteroids)
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Medications that raise blood sugar, such as corticosteroids, increase insulin and somatostatin, both of which inhibit growth hormone release and will reduce the effectiveness of CJC-1295.
Actionable advice:
Concurrent use is best avoided if possible, as the effectiveness of CJC-1295 will be significantly reduced.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/intervention/intermittent-fasting
Target name:
Intermittent Fasting
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
null
Description:
Fasting naturally lowers insulin and increases ghrelin, creating an ideal physiological environment for maximal growth hormone release when stimulated by CJC-1295.
Actionable advice:
Administer your dose during your fasting window for optimal results.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
informational_none
Target id:
/condition/carpal-tunnel-syndrome
Target name:
Carpal Tunnel Syndrome
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
A common side effect of elevated growth hormone is fluid retention, which can cause or exacerbate swelling and compression of the median nerve within the carpal tunnel.
Actionable advice:
Use should be discontinued if symptoms of carpal tunnel (hand numbness, pain) appear or worsen.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/biomarker/fasting-glucose
Target name:
Fasting Glucose
Severity:
moderate
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
Because growth hormone can impair insulin sensitivity, it is important to monitor fasting glucose and HbA1c to detect any negative changes in glucose metabolism.
Actionable advice:
Periodically check fasting glucose and HbA1c while using this peptide.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
monitor
Target id:
/intervention/resistance-training
Target name:
Resistance Training
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0.5
Hours after target:
0
Description:
Both resistance training and CJC-1295 stimulate growth hormone release; combining them may offer a modest synergistic benefit for recovery and muscle protein synthesis.
Actionable advice:
Consider administering your dose 30 minutes prior to a workout on an empty stomach.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
separate
Target id:
/biomarker/prolactin
Target name:
Prolactin
Severity:
minor
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
null
Description:
While less common with GHRH analogs than with some GHRPs, secretagogues can sometimes increase prolactin levels, which may warrant monitoring.
Actionable advice:
Consider checking prolactin levels, especially if symptoms like gynecomastia or lactation occur.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
monitor